MedTrace Logo

Erenumab for Idiosyncratic Facial Pain

NCT04249427 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2024-09-24

Study results available
· View outcomes & findings →

Summary

This is a phase IV randomized, double-blinded, placebo-controlled study to evaluate the efficacy of Erenumab in subjects with midfacial pain or pressure, without clinical or radiographic evidence of sinusitis.

Conditions

  • Facial Pain
  • Rhinosinusitis

Interventions

DRUG

Erenumab Prefilled Syringe

140mg Erenumab, pre-filled syringe given by subcutaneous injection

OTHER

Placebo

Placebo, pre-filled syringe given by subcutaneous injection

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • David Jang, M.D.

    lead OTHER

Principal Investigators

  • David Jang, MD · Duke Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-10
Primary Completion
2023-07-11
Completion
2023-07-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04249427 on ClinicalTrials.gov